C12N 9/0028
With nad or nadp as acceptor
Official title: {with NAD or NADP as acceptor (1.5.1)}
C12N9/0028 (With nad or nadp as acceptor) appears on 251 US grants and 309 published applications in this corpus.
Search patents in C12N- Granted patents
- 251
- Published applications
- 309
- Assignees
- 187
- Inventors
- 734
- Latest grant
- 4 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 2 | 0 |
| 1990 | 2 | 0 |
| 1991 | 5 | 0 |
| 1992 | 4 | 0 |
| 1993 | 3 | 0 |
| 1994 | 2 | 0 |
| 1995 | 3 | 0 |
| 1996 | 5 | 0 |
| 1997 | 5 | 0 |
| 1998 | 13 | 0 |
| 1999 | 3 | 0 |
| 2000 | 4 | 0 |
| 2001 | 10 | 2 |
| 2002 | 9 | 6 |
| 2003 | 11 | 6 |
| 2004 | 1 | 4 |
| 2005 | 2 | 6 |
| 2006 | 3 | 6 |
| 2007 | 3 | 7 |
| 2008 | 3 | 4 |
| 2009 | 1 | 2 |
| 2010 | 6 | 8 |
| 2011 | 0 | 4 |
| 2012 | 2 | 5 |
| 2013 | 5 | 5 |
| 2014 | 0 | 10 |
| 2015 | 7 | 14 |
| 2016 | 5 | 12 |
| 2017 | 10 | 10 |
| 2018 | 18 | 21 |
| 2019 | 15 | 23 |
| 2020 | 12 | 22 |
| 2021 | 10 | 23 |
| 2022 | 13 | 24 |
| 2023 | 11 | 22 |
| 2024 | 9 | 21 |
| 2025 | 21 | 24 |
| 2026 | 10 | 18 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Small molecules for dual function positron emission tomography (PET) and cell suicide switches4 Aug 2026US 12,697,403 B2The Trustees of the University of Pennsylvania
- Method of selecting a polypeptide of interest4 Aug 2026US 12,698,521 B2Imperial College Innovations Limited
- Biosynthesis of eriodictyol30 Jun 2026US 12,668,804 B2Conagen Inc.
- Microorganisms and methods for enhancing the availability of reducing equivalents in the presence of methanol, and for producing 1,4-butanediol related thereto30 Jun 2026US 12,668,820 B2Genomatica, Inc.
- Detection of environmental influences by bioluminescence2 Jun 2026US 12,644,104 B2Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen
- Analytical device for real time luminescence during temperature hold and ramp as used in real time cellular thermal shift assay1 Oct 2026US 2026/0297593 A1The United States of America, as represented by the Secretary, Department of Health and Human Serv
- Inducible programmed cell death-1 (pd1)-cytokine chimera for potentiated immune cell function24 Sep 2026US 2026/0284108 A1Seattle Children's Hospital d/b/a Seattle Children's Research Institute
- Production cell lines with targeted integration sites17 Sep 2026US 2026/0275373 A1Seagen Inc.
- Peptide expression constructs and uses thereof20 Aug 2026US 2026/0242414 A1Kyoto Prefectural Public University Corporation
- Modulation of genes coding for lysine ketoglutarate reductase20 Aug 2026US 2026/0242812 A1Philip Morris Products S. A.
Most cited
By later US patents
- Vaccinia DNA172US 5,017,487 AHoffmann-La Roche Inc. · 1991
- Human tissue plasminogen activator136US 4,766,075 AGenentech, Inc. · 1988
- Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues119US 6,586,207 B2California Institute of Technology · 2003
- Method of generating multiple protein variants and populations of protein variants prepared thereby96US 5,521,077 ALeland Stanford Junior University · 1996
- Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors79US 6,210,950 B1University of Medicine and Dentistry of New Jersey · 2001